References
- The National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395–409.
- Pinsky PF, Church TR, Izmirlian G, et al. The National Lung Screening Trial: results stratified by demographics, smoking history and lung cancer histology. Cancer. 2013;119:3976–3983.
- Paci E, Puliti D, Pegna AL, et al. Mortality, survival and incidence rates in the ITALUNG randomized lung cancer screening trial. Thorax. 2017;72:825–831.
- Infante M, Cavuto S, Lutman FR, et al. Long-term follow-up results of the DANTE Trial, a randomized study of lung cancer screening with spiral computed tomography. Am J Resp Criti Care Med. 2015;191:1166–1175.
- Wille MW, Dirksen A, Ashraf H, et al. Results of the randomized Danish Lung Cancer Screening Trial with focus on high-risk profiling. Am J Resp Criti Care Med. 2016;193:542–551.
- Pastorino U, Rossi M, Rosato V, et al. Annual or biennial CT screening versus observation in heavy smokers: 5-year results of the MILD trial. Eur J Cancer Prev. 2012;21:308–315.
- Yousaf-Kahn U, Van Der Aalst C, De Jong PA, et al. Final screening round of the NELSON lung cancer screening trial: the effect of a 2.5 year screening interval. Thorax. 2017;72:48–56.
- Rembold CM. Number needed to screen: development of a statistic for disease screening. Bmj. 1998;317:307–312.
- Pinsky PF, Berg C. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? J Med Screen. 2012;19:154–156.
- National Cancer Institute. Surveillance, epidemiology and end-results (SEER). Cancer Stat Rev. [ cited 2017 Oct 2]. Available from: https://seer.cancer.gov/csr/1975_2014/.
- Nelson HD, Fu R, Cantor A, et al. Effectiveness of breast cancer screening: systematic review and meta-analysis to update the 2009 U.S. Preventive Services Task Force Recommendation. Ann Int Med. 2016;164:244–255.
- Patz EF, Pinsky P, Gatsonis C, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Int Med. 2014;174:269–274.
- Christodoulou FL, Kazerooni EA. Radiation risk of lung cancer screening. Semin Respir Crit Care Med. 2013;34:738–747.
- Moyer VA. Screening for lung cancer: U.S. preventive services task force recommendation statement. Ann Int Med. 2014;160:330–338.
- Humphrey LL, Deffebach M, Pappas M, et al. Screening for lung cancer with low-dose computed tomography: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Int Med. 2013;159:411–420.
- Center for Medicare & Medicaid Services. MEDCAC meeting 4/30/2104 – lung cancer screening with low dose computed tomography. [cited 2017 Oct 2]. Available from: https://www.cms.gov/medicare-coverage-database/details/medcac-meeting-details.aspx?MEDCACId=68&bc=AgAIAAAAAAAAAA%3d%3d&.
- American College of Radiology. National radiology data registry. Quarterly Report, 30 Jun 2017. [cited 2017 Oct 2]. Available from: https://www.acr.org/~/media/ACR/Documents/PDF/QualitySafety/NRDR/Lung-Cancer-Screening-Practice-Registry/LCSRSemiAnnualFacilityReport.pdf.
- Kazerooni EA, Armstrong MR, Amorosa JK, et al. ACR CT accreditation program and the lung cancer screening program designation. J Amer Coll Radiol. 2015;12:273–276.
- Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment. Ann Intern Med. 2015;162:485–491.
- Kinsinger LS, Anderson C, Kim J, et al. Implementation of lung cancer screening in the Veterans Health Administration. JAMA Int Med. 2017;177:399–406.
- Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017;18:e754–766.
- Mazzone P, Powell CA, Arenberg D, et al. Components necessary for high-quality lung cancer screening: American College of Chest Physicians and American Thoracic Society policy statement. Chest. 2015;147:295–303.
- Wood DE, Kazerooni E, Baum SL, et al. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Cancer Netw. 2015;13:23–34.